|
| Real world evidence (RWE) is an essential tool for developing effective rare disease treatments. Regulators encourage its use. But a new survey from Syneos Health shows payers need persuading. |
|
| Many are unfamiliar with the terminology of RWE and worry about a lack of standards and transparency in single-arm studies and observational trials using RWE. |
|
|
What should the industry do? In a whitepaper, Syneos Health recommends:
|
|
| • |
Collaborative education efforts to boost literacy around RWE uses |
| • |
Transparent explanation of study protocols encouraging scientific feedback |
| • |
Broad use of expanded access programs to engage rare disease communities and generate longitudinal data |
|
|
|
The Syneos Health Insights Hub generates future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment. Driven by dynamic research, our perspectives are informed by our insights-driven product development model and crafted by subject matter experts focused on real answers to customer challenges to help guide decision making and investment. |
